Board of Directors

Uli Hacksell has been a member of the SynAct Board of Directors since 2020, and was elected chairman of the board at the AGM 2023. He has more than 30 years of experience from executive positions in major pharmaceutical and biotech companies and more than 10 years of experience as the CEO of publicly listed companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a professor of organic chemistry at Uppsala University. He holds a PhD from Uppsala University.

Dr. Hacksell is Chairman of the board of Medivir and Annexin Pharmaceuticals, and a board member of InDex Pharmaceuticals and Active Biotech.

Holdings: See this page for updated holdings

Kerstin Hasselgren is currently CFO of Xspray Pharma AB listed on Nasdaq Stockholm and has extensive experience from working in large public international companies such as VP Corporate Business Control at SSAB, CFO at Alstom Transport Nordic, VP Finance Global Operations at AstraZeneca and VP Finance Global R&D at AstraZeneca. Kerstin Hasselgren has a degree of Master of Science in Business and Economics from the Stockholm School of Economics.

Holdings: See this page for updated holdings

Ms. Bozilenko has over 30 years of investment banking and other healthcare industry expertise, including raising more than $30 billion in capital and executing numerous M&A transactions. She currently is President and CEO of Biothea Pharma, a biotechnology company. She is also a Strategic Advisor to William Blair & Company, a firm she joined in 2010 as Head of Biotech & Pharma and Managing Director. Prior to that, she worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group, at Banc of America Securities as a managing director and head of biotechnology, and at Vector Securities International, where she was a partner. Ms. Bozilenko was also a principal at Kidd & Company, a private-equity firm. She received her B.A. in molecular biology and M.A. in economic history from the University of Chicago. Ms. Bozilenko is currently a Director of AcelRx Pharmaceuticals (ACRX), SynAct Pharma (SYNACT), as well as NeuroNetworks Fund (NNF), a non-profit organization focused on therapies for autism, epilepsy, schizophrenia and related disorders. She also serves on the Advisory Board of Arctic Aurora Life Sciences, a Swedish healthcare-focused investment fund.

Holdings: See this page for updated holdings

Terje Kalland, MD, PhD, is a board member of SynAct since 2019. He has more than 30 years of international experience from management positions in the life science industry. Kalland has been senior vice president at Novo Nordisk A/S, head of research and development at Biovitrum AB (now SOBI AB), and has held various senior positions within Pharmacia AB., including global head of Oncology Research. He has substantial experience with financing and investment activities and as vice president at Karolinska Development AB. Dr. Kalland was professor in tumor immunology at Lund University and has experience with boards from several listed companies in Sweden and internationally.

Holdings: See this page for updated holdings

Thomas Jonassen, MD, is associate professor at cardiovascular pharmacology, University of Copenhagen, and visiting professor at William Harvey Research Institute, Barts and London School of Medicine. He has published more than 50 scientific publications and is the inventor of 6 granted patents in the US and Europe.

Dr. Jonassen is cofounder and current CSO and BoD member at SynAct Pharma AB, cofounder of ResoTher Pharma Aps, cofounder and former CSO at Action Pharma A/S, and cofounder of TXP Pharma AG. Action Pharma sold its lead drug development candidate to AbbVie for $110M USD and TXP Pharma sold various rights to Questcor Pharmaceuticals for $100M USD in milestone payments. Dr. Jonassen is coinventor of SynAct’s drug candidate, AP1189.

Holdings: Dr. Jonassen holds 61% of the shares in Bioinvest ApS and 100% of the shares in TJ Biotech Holding ApS. TJ Biotech Holding ApS holds 26.67% of the shares in GoodWind Holding GmbH. Bioinvest ApS, TJ Biotech Holding ApS, and GoodWind Holding GmbH hold shares in SynAct Pharma AB.   See this page for updated holdings

Thomas von Koch has extensive financial and leadership experience spanning over 30 years. Mr. von Koch is currently Interim CEO at global medtech company Bactiguard (listed on Nasdaq Stockholm), a company he co-founded in 2005, and of which he remains principal owner. Following two years at Investor AB, where he worked with corporate finance and mergers and acquisitions, he joined the global investment giant EQT as one of its initial team members. Mr. von Koch was CEO and Managing Partner of EQT from 2014 to 2019 and remains a member of several Investment Committees within EQT.

Mr. von Koch has a Master of Science in Business Administration from the Stockholm School of Economics and possess extensive board, investment, business transformation, and merger and acquisition experience.

Holdings: See this page for updated holdings